Nanobiotix Valuation Multiples

Nanobiotix Overview

About Nanobiotix

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Founded

2003

HQ

Employees

108

Website

nanobiotix.com

Sectors

BiopharmaceuticalsBioTechDeepTechHealthTech

Financials (LTM)

Revenue: $38M

EBITDA: ($18M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Nanobiotix Financials

Nanobiotix reported last 12-month revenue of $38M and negative EBITDA of ($18M).

In the same LTM period, Nanobiotix generated $38M in gross profit, ($18M) in EBITDA losses, and had net loss of ($24M).

Nanobiotix P&L

In the most recent fiscal year, Nanobiotix reported revenue of $38M and EBITDA of ($14M).

Nanobiotix expects next 12-month revenue of XXX and NTM EBITDA of XXX

Nanobiotix Stock Performance

Nanobiotix has current market cap of $2B, and enterprise value of $2B.

Nanobiotix's stock price is $33.79.

Nanobiotix Valuation Multiples

Nanobiotix trades at 44.3x EV/Revenue multiple, and (92.8x) EV/EBITDA.

Nanobiotix Financial Valuation Multiples

As of April 19, 2026, Nanobiotix has market cap of $2B and EV of $2B.

Equity research analysts estimate Nanobiotix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Nanobiotix has a P/E ratio of (67.8x).

Nanobiotix Margins & Growth Rates

Nanobiotix's revenue in the last 12 month grew by 20%.

Nanobiotix's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.

Nanobiotix's rule of 40 is (60%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Nanobiotix's rule of X is (43%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Nanobiotix Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Nanobiotix M&A Activity

Nanobiotix acquired XXX companies to date.

Last acquisition by Nanobiotix was on XXXXXXXX, XXXXX. Nanobiotix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Nanobiotix Investment Activity

Nanobiotix invested in XXX companies to date.

Nanobiotix made its latest investment on XXXXXXXX, XXXXX. Nanobiotix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).